NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Biotechnology · USD

Serina Therapeutics, Inc. (SER) Stock Analysis

Serina Therapeutics, Inc. (SER) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

SER

$1.77

+$0.11 (+6.63%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SER with… →

SER Key Statistics

As of Oct 21, 2026
Trading
Open
$1.67
Previous Close
$1.66
Day's Range
1.63–1.78
52-Week Range
1.22–5.29
Volume
39.77K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.16
Valuation
Market Cap
$44.96M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.87
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$19.18M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
25.40M
1-Year Return
−63.88%
Dividend and dates
Avg Volume
64.77K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SER closed at $1.77, −63.88% over 1 year.

Serina Therapeutics, Inc. (SER) has a market capitalization of $44.96M.

In fiscal 2025, SER reported revenue of $0.00.

SER Stock Return by Calendar Year

Serina Therapeutics, Inc. (SER) return since Nov 2018: what $10,000 became

1 year
$10,000 $3,612
−63.88%
5 years
$10,000 $548
−94.52%
Since Nov 2018
$10,000 $183
−98.17%

If you had invested $10,000 in Serina Therapeutics, Inc. (SER) at the close on November 29, 2018, the earliest close on record here, it would have been worth $183 at the close on October 21, 2026: −98.17% in total, −39.77% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−7.48%
2025−61.82%
2024−63.56%
2023−30.25%
2022−49.36%
2021−28.29%
2020−16.48%
2019−39.13%
2018 (partial year)+10.33%

As of October 21, 2026.

SER Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$19.18M—
2024$0.00−$11.14M—
2023$3.00M$5.27M175.6%
2022$500.00K−$2.68M−536.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$24.02M−$19.18M—
2024$0.00—−$17.05M−$11.14M—
2023$3.00M—−$3.13M$5.27M175.6%
2022$500.00K—−$2.27M−$2.68M−536.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Serina Therapeutics, Inc. (SER) is capitalised at $44.96M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 16 employees.

Over the past 52 weeks the price has ranged from $1.22 to $5.29. The most recent close on file for SER is $1.77, dated October 21, 2026. That is +$0.11 (+6.63%) against the previous close. The latest close sits 45.08% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $19.18M. Earnings per share on a trailing basis come to −1.87.

Across the 4 fiscal years on file, revenue moves from $500.00K in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is −63.88%. Measured over 5 years, that is −44.06% a year compounded. Beta against the wider market is reported at 0.16. Annualized volatility over the trailing 7 years is 132.47%.

Growth & Income

The record shows no dividend for SER.

2026 is still running; the total return is −7.48% year to date. Across the complete calendar years on file, 2020 returned −16.48% and 2024 returned −63.56%. Of the 7 complete calendar years on file, 0 finished higher.

Peer Comparison

Serina Therapeutics, Inc. (SER) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Serina Therapeutics, Inc. SER $44.96M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Serina Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Serina Therapeutics, Inc.

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

Visit website →